Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Non-Current Deffered Revenue of $8.9 million for Q1 2026, down 10.56% year-over-year from $10.0 million in Q1 2025, and down 1.83% quarter-over-quarter from $9.1 million in Q4 2025.
Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2026) Analysis & Trends
Collegium Pharmaceutical's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $8.9 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 10.56% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (down 10.56% YoY), while the FY2025 annual figure was $9.1 million, down 8.89% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $8.9 million, down from $9.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $10.0 million in Q3 2024, with the low at $8.9 million in Q1 2026.
- The 3-year median for Non-Current Deffered Revenue is $10.0 million (2024), against an average of $9.6 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue fell 7.22% in 2025, then dropped 10.56% in 2026.
- Collegium Pharmaceutical's Non-Current Deffered Revenue stood at $10.0 million in 2024, then declined by 8.89% to $9.1 million in 2025, then declined by 1.83% to $8.9 million in 2026.
- Business Quant data shows COLL's Non-Current Deffered Revenue at $8.9 million in Q1 2026, $9.1 million in Q4 2025, and $9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Collegium Pharmaceutical | 897.87 Mn | 748.55 Mn | 110.29 Mn | 8.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.78 Mn |
| Mar 31, 2026 | 8.94 Mn |
| Dec 31, 2025 | 9.11 Mn |
| Sep 30, 2025 | 9.28 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.00 Mn |